dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate sandoz 120 mg enterokapsel, hård
sandoz a/s - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; dimetylfumarat 120 mg aktiv substans
dimethyl fumarate sandoz 240 mg enterokapsel, hård
sandoz a/s - dimetylfumarat - enterokapsel, hård - 240 mg - propylenglykol hjälpämne; dimetylfumarat 240 mg aktiv substans
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
dimethyl fumarate teva
teva gmbh - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate newbury 240 mg enterokapsel, hård
newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne
dimethyl fumarate newbury 120 mg enterokapsel, hård
newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; propylenglykol hjälpämne
dimetylfumarat avansor 240 mg enterokapsel, hård
avansor pharma oy - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne
dimetylfumarat avansor 120 mg enterokapsel, hård
avansor pharma oy - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; dimetylfumarat 120 mg aktiv substans
dimethyl fumarate accord
accord healthcare s.l.u. - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).